News & Resources

Featured Stories

Pepperdine Graziadio Business School

Siren Biotechnology named a 2025 Most Fundable Company Read More

Press Releases | Posted on 5.12.25

Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Press Releases | Posted on 3.4.25

Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders

Press Releases | Posted on 11.18.24

Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Press Releases | Posted on 5.8.24

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Press Releases | Posted on 1.15.24

WhiteLab Genomics and Siren Biotechnology Announce Strategic Partnership to Accelerate AI-Powered Advancements in Gene Therapy

Press Releases | Posted on 11.1.23

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Press Releases | Posted on 5.17.23

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy

Press Releases | Posted on 5.17.23

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer